Novo Nordisk A S (NONOF) SEC filings

NONOFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVO

Financials through fiscal 2025, year ended Dec 31, 2025Score 4/30

$38.24−0.60 (-1.53%)

Close on Oct 19, 2026Market cap $170.76BP/E 11.1Yield –

SEC filings

40 of Novo Nordisk A S's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	6-K	Sep 30, 2026	Nov 4, 2026	SEC EDGAR
Current report	6-K	Nov 3, 2026	Nov 3, 2026	SEC EDGAR
Current report	6-K	Oct 26, 2026	Oct 26, 2026	SEC EDGAR
Current report	6-K	Oct 19, 2026	Oct 19, 2026	SEC EDGAR
Current report	6-K	Oct 12, 2023	Oct 13, 2026	SEC EDGAR
Current report	6-K	Oct 5, 2026	Oct 6, 2026	SEC EDGAR
Current report	6-K	Oct 2, 2026	Oct 5, 2026	SEC EDGAR
Current report	6-K	Sep 28, 2026	Sep 28, 2026	SEC EDGAR
Current report	6-K	Sep 21, 2026	Sep 21, 2026	SEC EDGAR
Current report	6-K	Sep 17, 2026	Sep 17, 2026	SEC EDGAR
Current report	6-K	Sep 14, 2026	Sep 15, 2026	SEC EDGAR
Current report	6-K	Sep 7, 2026	Sep 9, 2026	SEC EDGAR
Current report	6-K	Aug 31, 2026	Aug 31, 2026	SEC EDGAR
Current report	6-K	Aug 24, 2026	Aug 24, 2026	SEC EDGAR
Current report	6-K	Aug 17, 2026	Aug 18, 2026	SEC EDGAR
Current report	6-K	Aug 10, 2026	Aug 10, 2026	SEC EDGAR
Current report	6-K	Aug 6, 2026	Aug 10, 2026	SEC EDGAR
Current report	6-K	Aug 4, 2026	Aug 4, 2026	SEC EDGAR
Current report	6-K	Aug 4, 2026	Aug 4, 2026	SEC EDGAR
Current report	6-K	Jun 30, 2026	Aug 4, 2026	SEC EDGAR
Current report	6-K	Jul 31, 2026	Jul 31, 2026	SEC EDGAR
Current report	6-K	Jul 27, 2026	Jul 27, 2026	SEC EDGAR
Current report	6-K	Jul 20, 2026	Jul 21, 2026	SEC EDGAR
Current report	6-K	Jul 13, 2026	Jul 13, 2026	SEC EDGAR
Current report	6-K	Jul 6, 2026	Jul 6, 2026	SEC EDGAR
Current report	6-K	Jun 29, 2026	Jun 29, 2026	SEC EDGAR
Current report	6-K	Jun 22, 2026	Jun 24, 2026	SEC EDGAR
Current report	6-K	Jun 15, 2026	Jun 15, 2026	SEC EDGAR
Current report	6-K	Jun 8, 2026	Jun 8, 2026	SEC EDGAR
Current report	6-K	Jun 1, 2026	Jun 1, 2026	SEC EDGAR
Current report	6-K	May 26, 2026	May 27, 2026	SEC EDGAR
Current report	6-K	May 22, 2026	May 22, 2026	SEC EDGAR
Current report	6-K	May 22, 2026	May 22, 2026	SEC EDGAR
Current report	6-K	May 18, 2026	May 18, 2026	SEC EDGAR
Current report	6-K	May 12, 2026	May 13, 2026	SEC EDGAR
Current report	6-K	Mar 31, 2026	May 6, 2026	SEC EDGAR
Current report	6-K	May 5, 2026	May 5, 2026	SEC EDGAR
Current report	6-K	Apr 27, 2026	Apr 27, 2026	SEC EDGAR
Current report	6-K	Apr 20, 2026	Apr 20, 2026	SEC EDGAR
Current report	6-K	Apr 20, 2026	Apr 20, 2026	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Novo Nordisk A S's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Jan 31, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NONOF.

Compare: NONOF vs LLY · NONOF vs RDY · NONOF vs ABT · NONOF vs JNJ · NONOF vs MRK

Revenue growth6.4% · median 8.9%

Gross margin81.0% · median 69.7%

Company	Revenue	Growth
NONOF	309.06B DKK	+6.4%
JNJ	$99.34B	+7.8%
LLY	$86.46B	+45.5%
MRK	$67.38B	+4.9%
ABT	$48.23B	+10.0%
RDY	–	–

Company

Exchange: OTC
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 69,505
Auditor: Deloitte Statsautoriseret Revisionspartnerselskab
SEC CIK: 353278

Advertisement
300 × 250

See a number that looks wrong?